First Patient dosed in Ph 3 RASolve 308 Trial of Zoldonrasib + Pembrolizumab and Chemo in 1L Metastatic RAS G12D Non-Squamous NSCLC October 28, 2026
First Patients enrolled in Standard of Care Chemo Combination Cohorts of Global Ph 1/2 ASCEND Trial of CR-001 October 28, 2026
Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study October 28, 2026
University of California, Davis activated as a Clinical Trial Site for Ongoing Ph 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies October 27, 2026
Global Ph 2 Study of Ivonescimab in 1L Clear Cell RCC, Including Combination with Cadonilimab, initiated October 27, 2026
GOBLET Ph 1/2 study Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in H1 2027 October 20, 2026
First Patient Dosed in Hong Kong Clinical Trial of PLT012 for Liver Cancer Expansion October 20, 2026
First Patient dosed in Ph 3 RASolute 309 Trial of RASONQUE™ (daraxonrasib) + Zoldonrasib in 1L Metastatic RAS G12D Pancreatic Cancer October 14, 2026
Development of vispa-cel in R/R B cell NHL and CB-011 in R/R multiple myeloma to be discontinued October 14, 2026
First Patient Enrolled in Global Ph 3 Trial of Cadonilimab vs Nivolumab in 1L Gastric Cancer October 6, 2026
First patient dosed with LNK001 in Ph 1 study in patients with advanced or metastatic clear cell RCC October 6, 2026
Second Patient treated in the Fifth Cohort of Ovarian Cancer FSHR-targeted CAR-T Clinical Trial October 6, 2026
IDMC Recommends Continued Ph 2 Development of IMNN-001 Following Favorable Safety Review October 1, 2026
Target enrollment achieved in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma September 22, 2026
Ph 2 ALISCA®-Lung2 Trial of Alisertib + Paclitaxel Initiated for Patients with Advanced SCLC September 22, 2026
